Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — September 2025

Genmab — September 2025

Planlagt Fastgjort Låst Flyttet Genmab
283 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • SolsenS Offline
    SolsenS Offline
    Solsen
    wrote on sidst redigeret af
    #179

    Merus har et meget spændende stof i head and neck. Stoffet har read out på to fase 3 næste år. Så 2026 bliver det store read out år 😉

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #180

      yeah, it was one of the most prominent news at ASCO
      https://www.oncologypipeline.com/apexonco/asco-2025-preview-merus-tops-bicara

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #181

        ASCO25: Merus wins in head-to-head with Bicara for head and neck cancer https://finance.yahoo.com/news/asco-2025-merus-wins-head-105450309.html

        1 Reply Last reply
        0
        • L Offline
          L Offline
          lahn1
          wrote on sidst redigeret af
          #182

          Så slutter vores positive up trend. Det er slut med at prale af ingen gæld tvært imod blive Gmab nu et meget gælds tynget selskab men en financial leverage på > 5 😕 Det skal nok blive godt på den lamge bane men øv for trenden hvis jeg ikke tager meget fejl.

          1 Reply Last reply
          0
          • royalR Offline
            royalR Offline
            royal
            wrote on sidst redigeret af
            #183

            Håber du tager fejl. 🙂

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #184

              it does put some additional perspective on why some early clinical trials were deemed not good enough to proceed

              1 Reply Last reply
              0
              • nohopeN Offline
                nohopeN Offline
                nohope
                wrote on sidst redigeret af
                #185

                Vil undre mig meget hvis det ikke koster dyrt på kursen.

                1 Reply Last reply
                0
                • L Offline
                  L Offline
                  lahn1
                  wrote on sidst redigeret af
                  #186

                  Yes EL that was rettidigt omhu, as we say kn Denmark.

                  1 Reply Last reply
                  0
                  • L Offline
                    L Offline
                    lahn1
                    wrote on sidst redigeret af
                    #187

                    It sures raises some attention to Gmab with this size of M&A. And with the very succesfull Profound deal in the bag, hopefully market will trust Gmab judgement this time.

                    1 Reply Last reply
                    0
                    • B Offline
                      B Offline
                      BuyLow
                      wrote on sidst redigeret af
                      #188

                      The offices of Merus and Genmab are next to each other in Utrecht. They know each other well. GMAB has 3Bn cash, earning 1Bn a year, rising to 1,5Bn per year
                      in 2028. They can easily fund the debt based on recurring cashflow.

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #189

                        they are actually in the same building...

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #190

                          14/10 09:24
                          af E L
                          The new building next to the (also rather new...) Genmab R&D Center in Utrecht was opened. it will house Genmab, Merus and ImmunoPrecise Antibodies https://vastgoedberichten.nl/2023/10/13/kadans-opent-innovatiecentrum-accelerator-utrecht-op-utrecht-science-park/

                          1 Reply Last reply
                          0
                          • L Offline
                            L Offline
                            lahn1
                            wrote on sidst redigeret af
                            #191

                            Have we heard anything from the IPA collaboration ?

                            1 Reply Last reply
                            0
                            • L Offline
                              L Offline
                              lahn1
                              wrote on sidst redigeret af
                              #192

                              Markedet er meget uenige om

                              1 Reply Last reply
                              0
                              • SolsenS Offline
                                SolsenS Offline
                                Solsen
                                wrote on sidst redigeret af
                                #193

                                Det bør koste på kursen pga af størrelsen af købet.

                                1 Reply Last reply
                                0
                                • SolsenS Offline
                                  SolsenS Offline
                                  Solsen
                                  wrote on sidst redigeret af
                                  #194

                                  Genmab skal for første gang gældsætte sig eller sælge aktier for at finansiere købet.

                                  1 Reply Last reply
                                  0
                                  • nohopeN Offline
                                    nohopeN Offline
                                    nohope
                                    wrote on sidst redigeret af
                                    #195

                                    I bedste fald er udbytte eller tilbagekøb udskudt mindst 5 år.

                                    1 Reply Last reply
                                    0
                                    • T Offline
                                      T Offline
                                      transalp
                                      wrote on sidst redigeret af
                                      #196

                                      Men tror vi på genmab, er det jo mere menig i udvidelse, snare end udbytte og tilbagekøb. Men giver en lille trækning, når man tænker på fabrikken i USA..

                                      1 Reply Last reply
                                      0
                                      • L Offline
                                        L Offline
                                        lahn1
                                        wrote on sidst redigeret af
                                        #197

                                        @buylow, ja de kommer hurtigt ned på et acceptabelt gældsniveau som de selv siger mindre end 3 i 2027. Darzalex royalties lægger en sikker bund og øger troværdigheden af tilbagebetalingen af lånet.

                                        1 Reply Last reply
                                        0
                                        • nohopeN Offline
                                          nohopeN Offline
                                          nohope
                                          wrote on sidst redigeret af
                                          #198

                                          Tror vi på Jan? Ham der sagde at vi ville få ret i voldgifterne ? Ham der ville forklare JnJ at de skulle købe SuperDara ?

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper